Health Condition 1: null- Recurrent Dermatophytosis Of Skin- Tinea Cruris and Corporis
Conditions
Interventions
Intervention1: Group A: groupA- isotretinoin(0.5mg/kg) once daily and Terbinafine 250 mg twice daily for a period of 4 weeks.
Control Intervention1: group B: Group B: terbinafine at 250 mg twice daiy
Sponsors
AIIMS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients >= 18 years of age with tinea cruris and/or tinea corporis. 2) KOH (10%) positivity by microscopy from the lesion during the time of presentation. 3) Two or more episodes in one year. 4) Patients consenting to participate in the study.
Exclusion criteria
Exclusion criteria: 1) Not willing to consent and follow up for the study. 2) Patients who have received any topical antifungal therapy within last 2 weeks or oral antifungal therapy in the previous 4 weeks. 3) Immunocompromised patients. 4) Patients with known active liver, cardiac, renal or neurological diseases or uncontrolled diabetes Mellitus. 5) Hypersensitivity to either isotretinoin or terbinafine. 6) Pregnant and lactating women. 7) Women desiring pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rates of infection both clinically and microbiologiically in both the groupsTimepoint: After 4 weeks/ 6 weeks of treatment and after 3 months follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) species identification 2) side effects of treatmentTimepoint: After 4 weeks/ 6 weeks of treatment and at 3 months follow up | — |
Countries
India
Contacts
Public ContactDr Gridharan senthilnathan
All India Institute Of Medical Sciences, New Delhi
Outcome results
None listed